Stachydrine is effective and selective against blast phase chronic myeloid leukaemia through inhibition of multiple receptor tyrosine kinases

CONTEXT: Resistance to BCR-ABL tyrosine kinase inhibitor (TKI) is the cause of treatment failure in blast phase chronic myeloid leukaemia (BP-CML). Agents that act synergistically with BCR-ABL TKI are required to improve response. OBJECTIVE: This work investigated the effects of stachydrine in CML....

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Ruixin, Zhang, Wei, Xu, Dandan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967197/
https://www.ncbi.nlm.nih.gov/pubmed/35348419
http://dx.doi.org/10.1080/13880209.2022.2044862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967197/
https://www.ncbi.nlm.nih.gov/pubmed/35348419
http://dx.doi.org/10.1080/13880209.2022.2044862

Ejemplares similares